{
    "clinical_study": {
        "@rank": "107551", 
        "acronym": "VIDA", 
        "arm_group": [
            {
                "arm_group_label": "Vildagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Vildagliptin  50 mg twice daily (bid) + Insulin 20 to 40 IU/day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess if the addition of vildagliptin as add-on therapy\n      improves glucose variability in type 2 diabetes mellitus (T2DM) patients inadequately\n      controlled with insulin, with special emphasis in hypoglycemic episodes measured by\n      continuous glucose monitoring."
        }, 
        "brief_title": "Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Informed consent read and signed before any protocol procedure.\n\n          2. Free will to sign the informed consent.\n\n          3. Male and female between 18 and 80 years. If female, patient must be non-fertile or of\n             childbearing potential using a medically approved birth control method.\n\n          4. Type 2 diabetes mellitus\n\n          5. Patient under insulin treatment within 3 years with stable insulin NPH (Neutral\n             ProtamineHagedorn) regimen at dose of at least 20 UI/day up to 40 UI/day for a\n             minimum of 4 weeks prior to enrolment, only NPH and glargine insulin are allowed.\n\n          6. HbA1c between 7.5 to 9%.\n\n          7. Fasting plasma glucose (FPG) less than 270 mg/dL.\n\n          8. Body mass index (BMI) between 20 to 35 kg/m2.\n\n          9. Free willing to take the vildagliptin tablets during the study.\n\n        Exclusion Criteria\n\n          1. Pregnant or lactating female or without birth control method if of childbearing\n             potential.\n\n          2. Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms\n             of diabetes, e.g., Cushing's syndrome.\n\n          3. Acute cardiovascular complications or metabolic complications within the past 4\n             months.\n\n          4. History cerebrovascular disease during the last year.\n\n          5. History of Torsades de Points, ventricular tachycardia or ventricular fibrillation.\n\n          6. Ischemic heart disease (e.g. myocardial infarction, unstable angina, coronary artery\n             bypass surgery).\n\n          7. Congestive heart failure requiring pharmacologic treatment.\n\n          8. Any known serious heart condition.\n\n          9. ALT and/or AST greater than three times the upper limit of the normal range.\n\n         10. Serum creatinine levels greater than 1.5 mg/dL\n\n         11. Malignancy including leukemia and lymphoma within the last 5 years\n\n        Other inlcusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "238", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862263", 
            "org_study_id": "CLAF237AMX01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vildagliptin", 
                "description": "Orally active and highly selective inhibitor of DPP-4", 
                "intervention_name": "Vildagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Vildagliptin", 
                    "Placebo"
                ], 
                "description": "Long- acting human insulin analog indicated to improve glycemic control", 
                "intervention_name": "Insulin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo of vildagliptin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vildagliptin", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes,", 
            "Type 2 diabetes,", 
            "Diabetes mellitus,", 
            "insulin,"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ciudad De Mexico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "11850"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ciudad De Mexico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "06600"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "06700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "07300"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "14050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metepec", 
                        "country": "Mexico", 
                        "state": "Edo. de M\u00e9xico", 
                        "zip": "52140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Celaya", 
                        "country": "Mexico", 
                        "state": "Guanajuato", 
                        "zip": "38 000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico", 
                        "state": "Jalisco", 
                        "zip": "44150"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico", 
                        "state": "Jalisco", 
                        "zip": "44600"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico", 
                        "state": "Jalisco", 
                        "zip": "44670"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadaljara", 
                        "country": "Mexico", 
                        "state": "Jalisco", 
                        "zip": "44140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico", 
                        "state": "Nuevo Leon", 
                        "zip": "64710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cadereyta Jimenez", 
                        "country": "Mexico", 
                        "state": "Nuevo Le\u00f3n", 
                        "zip": "67450"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico", 
                        "state": "Nuevo Le\u00f3n", 
                        "zip": "64020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico", 
                        "state": "Nuevo Le\u00f3n", 
                        "zip": "64460"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cancun", 
                        "country": "Mexico", 
                        "state": "Quintana Roo", 
                        "zip": "77506"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Culiac\u00e1n", 
                        "country": "Mexico", 
                        "state": "Sinaloa", 
                        "zip": "80000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matamoros", 
                        "country": "Mexico", 
                        "state": "Tamaulipas", 
                        "zip": "87300"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Merida", 
                        "country": "Mexico", 
                        "state": "Yucat\u00e1n", 
                        "zip": "97133"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Puebla", 
                        "country": "Mexico", 
                        "zip": "72190"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double-Blind, Randomized, Parallel-Group Placebo-Controlled Study to Compare the Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Insulin.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Mexican Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "An hypoglycemic event is defined as any continuous glucose monitoring (CGM) measurement less than 60 mg/dL and a hyperglycemic is define as any CGM greater than 140 mg/dL.", 
            "measure": "Percentage of patients with hyperglycemic events evaluated with CGM", 
            "safety_issue": "Yes", 
            "time_frame": "At 13 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862263"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "An episode of hypoglycemia is defined as any value of glucose under 60 mg/dL, an episode of hyperglycemia is defined as any value of glucose above 140mg/dL measured by CGM.", 
                "measure": "Number of hypoglycemia and/or hyperglycemia measured by CGM", 
                "safety_issue": "Yes", 
                "time_frame": "13 weeks"
            }, 
            {
                "description": "Duration and intensity of hypoglycemic episodes, measured as area under the curve (AUC 0-24) of the excursions of glucose values below 60 mg/dl per day, measured by continuous glucose monitoring", 
                "measure": "Area under the curve (AUC 0-24) of the excursions of glucose values below 60 mg/dl per day", 
                "safety_issue": "Yes", 
                "time_frame": "0 to 24 hours daily for week 1, 4 and 13"
            }, 
            {
                "description": "Change from baseline", 
                "measure": "Average of insulin units per day administered during the study", 
                "safety_issue": "Yes", 
                "time_frame": "13 weeks"
            }, 
            {
                "description": "Lipid Profile will include total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol", 
                "measure": "Changes from the baseline in Lipid Profile", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "description": "Weight will be measured on Kg.", 
                "measure": "Change from baseline in Body weight", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "description": "BP will be mesured on mmHg", 
                "measure": "Change from baseline in Blood pressure (BP),", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "description": "FPG will be measured on mg/dL", 
                "measure": "Change from baseline in Fasting plasma glucose (FPG),", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "description": "HbA1c will be measured on %", 
                "measure": "Change from baseline in Hemoglobin A1C (HbA1c)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "description": "Creatinine will be measured on mg/dL", 
                "measure": "Change from baseline in Creatinine", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "description": "C-Peptide will be measured on microIU/mL", 
                "measure": "Change from baseline in C-peptide", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "description": "ALT/AST will be measured on ratio.", 
                "measure": "Changes from baseline in alanine aminotransferase (ALT)/aspartate aminotransferase (AST)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 week"
            }, 
            {
                "description": "Bilirubin will be measure on mg/dL", 
                "measure": "Changes from baseline in Direct bilirubin", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "measure": "Changes from baseline in Body Mass Index (BMI)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 13 weeks"
            }, 
            {
                "measure": "Number of patients with adverse events, serious adverse events and death as evaluation of safety and tolerability of coadministration of vildagliptin with insulin", 
                "safety_issue": "Yes", 
                "time_frame": "13 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}